[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357739-105":59,"doc-detail-357739-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-review-article","Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer - review article","","Total neoadjuvant therapy (TNT) has emerged as a key treatment paradigm for locally advanced rectal cancer, reducing distant metastasis rates and enabling organ preservation in selected patients. Responses vary substantially, creating a need for biomarkers to guide treatment selection and improve outcomes. This narrative review synthesises evidence on tumour-intrinsic genomic, transcriptomic, and molecular predictors, including somatic mutations, germline polymorphisms, gene-expression profiles, MMR status, protein and epigenetic markers, and circulating tumour-derived biomarkers across CRT and TNT approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-review-article/357739/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-review-article/357739.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this narrative review?","Question",{"text":112,"@type":113},"To comprehensively summarise molecular associations with response to total neoadjuvant therapy (TNT) in locally advanced rectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarker categories are evaluated for predicting response to neoadjuvant therapy?",{"text":117,"@type":113},"Tumour-intrinsic genomic biomarkers, transcriptomic markers, mismatch repair (MMR) status, protein and epigenetic markers, and circulating tumour-derived biomarkers such as circulating tumour DNA.",{"name":119,"@type":110,"acceptedAnswer":120},"How do circulating tumour DNA (ctDNA) findings relate to treatment response?",{"text":121,"@type":113},"Dynamic ctDNA monitoring, especially ctDNA clearance during or after therapy, is consistently associated with pathological response and long-term oncologic outcomes, while baseline ctDNA levels show limited predictive value.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357739,1790508827,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Medical Oncology (2026) 43:237  \n[https://doi.org/10.1007/s12032-026-03354-y](https://doi.org/10.1007/s12032-026-03354-y)  \nREVIEW ARTICLE  \nGenomic, transcriptomic, and molecular predictors of response toneoadjuvant therapy in locally advanced rectal cancer: a narrative review  \nSarah S. Tang1 · Yuying Bi1 · Dedrick Kok Hong Chan1,2,3  \nReceived: 6 May 2026 / Accepted: 29 July 2026 / Published online: 7 August 2026 © The Author(s) 2026  \nAbstract  \nTotal neoadjuvant therapy (TNT) has emerged as a key treatment paradigm for locally advanced rectal cancer, reducing distant metastasis rates and facilitating organ preservation in selected patients. However, treatment response remains heterogeneous, highlighting the need for biomarkers that can guide treatment selection and optimise outcomes. This narrative review synthesises the current evidence regarding tumour-intrinsic genomic biomarkers associated with response to neoadjuvant therapy, encompassing somatic mutations, germline polymorphisms, gene expression profiles, mismatch repair (MMR) status, protein expression, epigenetic markers, and circulating tumour-derived biomarkers across conventional chemoradiotherapy (CRT) and TNT paradigms. Across the reviewed literature, individual somatic mutations, including KRAS, TP53, and BRAF, demonstrated limited reproducibility as predictive biomarkers, although KRAS mutations were recurrently associated with lower pathological complete response (pCR) rates in CRT-era cohorts. Germline polymorphisms in DNA repair (XRCC1) and folate metabolism (MTHFR) genes showed inconsistent associations with treatment response. In contrast, transcriptomic biomarkers demonstrated greater biological coherence, with proliferative, epithelial–mesenchymal transition, and metabolic signatures frequently associated with treatment resistance, while multi-gene classifiers generally outperformed single-gene markers. Among currently available tumour-intrinsic biomarkers, MMR deficiency was the most consistently reported biomarker associated with reduced response to fluoropyrimidine-based regimens, including TNT, although TNT-specific evidence remains comparatively limited. Dynamic circulating tumour DNA (ctDNA) monitoring, particularly ctDNA clearance during or after therapy, was consistently associated with pathological response and long-term oncologic outcomes across reviewed studies, whereas baseline ctDNA levels showed limited predictive value. Overall, the reviewed literature suggests that biomarker research in rectal cancer has evolved from single-gene analyses towards pathway-level and dynamic biomarkers. The integration of transcriptomic signatures, MMR status, and dynamic ctDNA monitoring may represent a promising strategy for personalising neoadjuvant therapy, improving patient selection for organ-preserving approaches, and enhancing oncologic outcomes in locally advanced rectal cancer. Nevertheless, the evidence base remains heterogeneous, and further prospective validation, assay standardisation, and evaluation within contemporary TNT cohorts are required before these biomarkers can be routinely incorporated into clinical decision-making.  \nKeywords Neoadjuvant therapy · Rectal cancer · Genomics · Transcriptomics · Treatment · Review  \n Dedrick Kok Hong Chan [surckhd@nus.edu.sg](surckhd@nus.edu.sg)  \n1 Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore  \n2 NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore  \n3 Division of Colorectal Surgery, Department of Surgery, National University Hospital, Singapore, Singapore  \nIntroduction  \nIn recent years, total neoadjuvant therapy (TNT) has become standard of care in the management of rectal cancer. In the TNT regimen, chemoradiotherapy (CRT) is administered prior to surgical total mesorectal excision (TME) . Evidence from the RAPIDO [1] and PRODIGE23 [2] trials suggests that the key","cbCaiaffCYtjXJRw","https://ap.wps.com/l/cbCaiaffCYtjXJRw","pdf",926658,13,"English","# Abstract\n# Introduction\n## TNT as standard of care\n## Clinical factors linked to poor response\n## Molecular determinants and review objective","[{\"question\":\"What is the purpose of this narrative review?\",\"answer\":\"To comprehensively summarise molecular associations with response to total neoadjuvant therapy (TNT) in locally advanced rectal cancer.\"},{\"question\":\"Which biomarker categories are evaluated for predicting response to neoadjuvant therapy?\",\"answer\":\"Tumour-intrinsic genomic biomarkers, transcriptomic markers, mismatch repair (MMR) status, protein and epigenetic markers, and circulating tumour-derived biomarkers such as circulating tumour DNA.\"},{\"question\":\"How do circulating tumour DNA (ctDNA) findings relate to treatment response?\",\"answer\":\"Dynamic ctDNA monitoring, especially ctDNA clearance during or after therapy, is consistently associated with pathological response and long-term oncologic outcomes, while baseline ctDNA levels show limited predictive value.\"}]","Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer - review article | PDF",1790131600,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c631254027cfd4cd37cd18f182887fda.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ad6819a47055fd323e0290f13b19247.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdd96ccddf639b66542e6e645a70634a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/024f9bb7e7bbbce93df551ccaca21e00.webp",980,1301]